A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines

There is no effective therapy for the lately increased incidence of glioblastoma multiforme (GBM)—the most common primary brain tumor characterized by a high degree of invasiveness and genetic heterogeneity. Currently, DNA alkylating agent temozolomide (TMZ) is the standard chemotherapy. Nevertheles...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandt, Barbara, Németh, Marica, Berta, Gergely, Szünstein, Máté, Heffer, Marija, Rauch, Tibor A., Pap, Marianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178391/
https://www.ncbi.nlm.nih.gov/pubmed/37175636
http://dx.doi.org/10.3390/ijms24097929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178391/
https://www.ncbi.nlm.nih.gov/pubmed/37175636
http://dx.doi.org/10.3390/ijms24097929

Ejemplares similares